GraniteShares 1.5x Long Coinbase Daily ETF

VS TR 2x Long VIX Futures ETF

Direxion Daily Semicondct Bear 3X ETF

ProShares Ultra VIX Short-Term Futures

iPath S&P 500 VIX ST Futures ETN

GraniteShares 1.5x Short NVDA Daily ETF

ARK Genomic Revolution Multi-Sector ETF

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Technology Bear 3X Shares

ProShares UltraPro Short QQQ

Direxion Daily Semicondct Bull 3X ETF

ProShares Ultra Semiconductors

GraniteShares 1.5x Long META Daily ETF

Direxion Daily TSLA Bull 1.5X Shares

VS TR -1x Short VIX Futures ETF

GraniteShares 1.5x Long NVDA Daily ETF

Altimmune Inc. Common Stock

Mast Therapeutics, Inc.

ProShares UltraPro QQQ

ProShares Short VIX Short-Term Futures

Siyata Mobile Inc. Common Shares

Capstone Holding Corp. Common Stock

Amesite Inc. Common Stock

Virgin Galactic Holdings Inc. Common Stock

Pasithea Therapeutics Corp. Common Stock

Gryphon Digital Mining Inc Common Stock

Classover Holdings Inc. Class B Common Stock

CoreWeave Inc. Class A Common Stock

Applied Digital Corporation Common Stock

Luminar Technologies Inc.  Class A Common Stock

Click Holdings Limited Ordinary Share

Crown LNG Holdings Limited Ordinary Shares

Incannex Healthcare Limited American Depositary Shares

Aytu BioPharma Inc.  Common Stock

Asset Entities Inc. Class B Common Stock

Next Technology Holding Inc. Ordinary Shares

Nuvve Holding Corp. Common Stock

MicroAlgo Inc. Ordinary Shares

Kindly MD Inc. Common Stock

ZK International Group Co. Ltd Ordinary Share

Click here to get full coverage on Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives - Yahoo Finance

Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives  Yahoo Finance

Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives - Yahoo Finance

Click here to get full coverage on Genmab (GMAB) Receives Revised Price Target from H.C. Wainwright - GuruFocus

Genmab (GMAB) Receives Revised Price Target from H.C. Wainwright  GuruFocus

Genmab (GMAB) Receives Revised Price Target from H.C. Wainwright - GuruFocus

Click here to get full coverage on Where are the Opportunities in (GMAB) - news.stocktradersdaily.com

Where are the Opportunities in (GMAB)  news.stocktradersdaily.com

Where are the Opportunities in (GMAB) - news.stocktradersdaily.com

Click here to get full coverage on New Analyst Forecast: $GMAB Given 'Buy' Rating - Nasdaq

New Analyst Forecast: $GMAB Given 'Buy' Rating  Nasdaq

New Analyst Forecast: $GMAB Given 'Buy' Rating - Nasdaq

Click here to get full coverage on Genmab Executes Share Buy-back Transactions in May 2025 - MSN

Genmab Executes Share Buy-back Transactions in May 2025  MSN

Genmab Executes Share Buy-back Transactions in May 2025 - MSN

Click here to get full coverage on Genmab's New Lymphoma Treatment Achieves Breakthrough Results in Phase 3 Trial, FDA Filing Imminent - Stock Titan

Genmab's New Lymphoma Treatment Achieves Breakthrough Results in Phase 3 Trial, FDA Filing Imminent  Stock Titan

Genmab's New Lymphoma Treatment Achieves Breakthrough Results in Phase 3 Trial, FDA Filing Imminent - Stock Titan

Click here to get full coverage on Institutional owners may take dramatic actions as Genmab A/S' (CPH:GMAB) recent 7.8% drop adds to one-year losses - simplywall.st

Institutional owners may take dramatic actions as Genmab A/S' (CPH:GMAB) recent 7.8% drop adds to one-year losses  simplywall.st

Institutional owners may take dramatic actions as Genmab A/S' (CPH:GMAB) recent 7.8% drop adds to one-year losses - simplywall.st

Click here to get full coverage on Transactions in Connection with Share Buy-back Program - GlobeNewswire

Transactions in Connection with Share Buy-back Program  GlobeNewswire

Transactions in Connection with Share Buy-back Program - GlobeNewswire

Click here to get full coverage on Is Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now? - Yahoo Finance

Is Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now?  Yahoo Finance

Is Genmab A/S (GMAB) the Most Profitable Growth Stock to Buy Now? - Yahoo Finance

Click here to get full coverage on Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now? - Yahoo Finance

Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?  Yahoo Finance

Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now? - Yahoo Finance

Click here to get full coverage on Genmab to Present New and Updated Results from its Robust Epcori - GuruFocus

Genmab to Present New and Updated Results from its Robust Epcori  GuruFocus

Genmab to Present New and Updated Results from its Robust Epcori - GuruFocus

Click here to get full coverage on Why Genmab A/S (GMAB) Is Among the Best Healthcare Stocks To Buy According to Analysts - Yahoo Finance

Why Genmab A/S (GMAB) Is Among the Best Healthcare Stocks To Buy According to Analysts  Yahoo Finance

Why Genmab A/S (GMAB) Is Among the Best Healthcare Stocks To Buy According to Analysts - Yahoo Finance

Click here to get full coverage on Genmab (GMAB) Upgraded to Buy, Undervalued with Growth Potential - GuruFocus

Genmab (GMAB) Upgraded to Buy, Undervalued with Growth Potential  GuruFocus

Genmab (GMAB) Upgraded to Buy, Undervalued with Growth Potential - GuruFocus

Click here to get full coverage on Should Value Investors Buy Genmab (GMAB) Stock? - Yahoo Finance

Should Value Investors Buy Genmab (GMAB) Stock?  Yahoo Finance

Should Value Investors Buy Genmab (GMAB) Stock? - Yahoo Finance

Click here to get full coverage on GMAB Expands Global Reach with Key Approvals and Promising Data | GMAB Stock News - GuruFocus

GMAB Expands Global Reach with Key Approvals and Promising Data | GMAB Stock News  GuruFocus

GMAB Expands Global Reach with Key Approvals and Promising Data | GMAB Stock News - GuruFocus

Click here to get full coverage on Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts? - Yahoo Finance

Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?  Yahoo Finance

Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts? - Yahoo Finance

Click here to get full coverage on Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance

Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...  Yahoo Finance

Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance

Click here to get full coverage on Is Genmab A/S (GMAB) the Best Cash-Rich Undervalued Stock to Invest In? - Yahoo Finance

Is Genmab A/S (GMAB) the Best Cash-Rich Undervalued Stock to Invest In?  Yahoo Finance

Is Genmab A/S (GMAB) the Best Cash-Rich Undervalued Stock to Invest In? - Yahoo Finance

Click here to get full coverage on Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025 - Yahoo Finance

Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025  Yahoo Finance

Genmab (CPSE:GMAB) Reports US$3 Billion DARZALEX Sales For Q1 2025 - Yahoo Finance

Click here to get full coverage on Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st

Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year  simplywall.st

Genmab A/S Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st

Click here to get full coverage on J&J Passes on Genmab's HexaBody-CD38, Development Halted Despite 55% Response Rate - Stock Titan

J&J Passes on Genmab's HexaBody-CD38, Development Halted Despite 55% Response Rate  Stock Titan

J&J Passes on Genmab's HexaBody-CD38, Development Halted Despite 55% Response Rate - Stock Titan

Click here to get full coverage on Why Is Genmab A/S (GMAB) Among the Worst Performing Healthcare Stocks in 2024? - Yahoo Finance

Why Is Genmab A/S (GMAB) Among the Worst Performing Healthcare Stocks in 2024?  Yahoo Finance

Why Is Genmab A/S (GMAB) Among the Worst Performing Healthcare Stocks in 2024? - Yahoo Finance

Click here to get full coverage on Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Genmab (GMAB) Upgraded to Buy: Here's What You Should Know  Yahoo Finance

Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

Click here to get full coverage on Genmab stock price target cut to $35 at H.C. Wainwright By Investing.com - Investing.com Nigeria

Genmab stock price target cut to $35 at H.C. Wainwright By Investing.com  Investing.com Nigeria

Genmab stock price target cut to $35 at H.C. Wainwright By Investing.com - Investing.com Nigeria

Click here to get full coverage on (GMAB) Trading Signals - news.stocktradersdaily.com

(GMAB) Trading Signals  news.stocktradersdaily.com

(GMAB) Trading Signals - news.stocktradersdaily.com

Click here to get full coverage on Genmab Stock: Positive 2025 Outlook, J&J’s Decision Coming Soon (NASDAQ:GMAB) - Seeking Alpha

Genmab Stock: Positive 2025 Outlook, J&J’s Decision Coming Soon (NASDAQ:GMAB)  Seeking Alpha

Genmab Stock: Positive 2025 Outlook, J&J’s Decision Coming Soon (NASDAQ:GMAB) - Seeking Alpha

Click here to get full coverage on Genmab Announces Initiation of Share Buy-Back Program - GlobeNewswire

Genmab Announces Initiation of Share Buy-Back Program  GlobeNewswire

Genmab Announces Initiation of Share Buy-Back Program - GlobeNewswire

Click here to get full coverage on Genmab’s Outlook Beyond Darzalex's Patent Cliff (NASDAQ:GMAB) - Seeking Alpha

Genmab’s Outlook Beyond Darzalex's Patent Cliff (NASDAQ:GMAB)  Seeking Alpha

Genmab’s Outlook Beyond Darzalex's Patent Cliff (NASDAQ:GMAB) - Seeking Alpha

Click here to get full coverage on Why Is Genmab A/S (GMAB) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance

Why Is Genmab A/S (GMAB) Among the Worst Performing Biotech Stocks in 2024?  Yahoo Finance

Why Is Genmab A/S (GMAB) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance

Click here to get full coverage on Genmab First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - simplywall.st

Genmab First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag  simplywall.st

Genmab First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - simplywall.st

Click here to get full coverage on Genmab AS (GMAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Pipeline ... - Yahoo Finance

Genmab AS (GMAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Pipeline ...  Yahoo Finance

Genmab AS (GMAB) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Pipeline ... - Yahoo Finance

Click here to get full coverage on HSBC Adjusts Price Target for Genmab (GMAB) Amid Potential Earni - GuruFocus

HSBC Adjusts Price Target for Genmab (GMAB) Amid Potential Earni  GuruFocus

HSBC Adjusts Price Target for Genmab (GMAB) Amid Potential Earni - GuruFocus

Click here to get full coverage on Genmab: GEN3014’s Demise And Implications For The HexaBody Platform (NASDAQ:GMAB) - Seeking Alpha

Genmab: GEN3014’s Demise And Implications For The HexaBody Platform (NASDAQ:GMAB)  Seeking Alpha

Genmab: GEN3014’s Demise And Implications For The HexaBody Platform (NASDAQ:GMAB) - Seeking Alpha

Click here to get full coverage on Earnings Flash (GMAB) Genmab Posts Q1 EPS $3.05 - marketscreener.com

Earnings Flash (GMAB) Genmab Posts Q1 EPS $3.05  marketscreener.com

Earnings Flash (GMAB) Genmab Posts Q1 EPS $3.05 - marketscreener.com

Click here to get full coverage on Transactions with shares and linked securities in Genmab - GlobeNewswire

Transactions with shares and linked securities in Genmab  GlobeNewswire

Transactions with shares and linked securities in Genmab - GlobeNewswire

Click here to get full coverage on Genmab stock upgraded at William Blair post J&J exit (GMAB) - Seeking Alpha

Genmab stock upgraded at William Blair post J&J exit (GMAB)  Seeking Alpha

Genmab stock upgraded at William Blair post J&J exit (GMAB) - Seeking Alpha

Click here to get full coverage on Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround - Yahoo Finance

Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround  Yahoo Finance

Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround - Yahoo Finance

Click here to get full coverage on The past three years for Genmab (CPH:GMAB) investors has not been profitable - simplywall.st

The past three years for Genmab (CPH:GMAB) investors has not been profitable  simplywall.st

The past three years for Genmab (CPH:GMAB) investors has not been profitable - simplywall.st

Click here to get full coverage on Genmab A/S: Circling Back On This Complicated Story (NASDAQ:GMAB) - Seeking Alpha

Genmab A/S: Circling Back On This Complicated Story (NASDAQ:GMAB)  Seeking Alpha

Genmab A/S: Circling Back On This Complicated Story (NASDAQ:GMAB) - Seeking Alpha

Click here to get full coverage on Genmab Stock Is Too Attractive To Ignore (NASDAQ:GMAB) - Seeking Alpha

Genmab Stock Is Too Attractive To Ignore (NASDAQ:GMAB)  Seeking Alpha

Genmab Stock Is Too Attractive To Ignore (NASDAQ:GMAB) - Seeking Alpha

Click here to get full coverage on What Analysts Are Saying About Genmab Stock - Nasdaq

What Analysts Are Saying About Genmab Stock  Nasdaq

What Analysts Are Saying About Genmab Stock - Nasdaq

Click here to get full coverage on Transactions In Connection with Share Buy-back Program - GlobeNewswire

Transactions In Connection with Share Buy-back Program  GlobeNewswire

Transactions In Connection with Share Buy-back Program - GlobeNewswire

Click here to get full coverage on Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives By GuruFocus - Investing.com Canada

Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives By GuruFocus  Investing.com Canada

Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives By GuruFocus - Investing.com Canada

Click here to get full coverage on Breakthrough: Japan Approves Revolutionary Cervical Cancer Drug TIVDAK with 30% Survival Benefit - Stock Titan

Breakthrough: Japan Approves Revolutionary Cervical Cancer Drug TIVDAK with 30% Survival Benefit  Stock Titan

Breakthrough: Japan Approves Revolutionary Cervical Cancer Drug TIVDAK with 30% Survival Benefit - Stock Titan

Click here to get full coverage on Genmab (GMAB) Sees Strong Q1 Sales from Darzalex Boosting Royalt - GuruFocus

Genmab (GMAB) Sees Strong Q1 Sales from Darzalex Boosting Royalt  GuruFocus

Genmab (GMAB) Sees Strong Q1 Sales from Darzalex Boosting Royalt - GuruFocus

Click here to get full coverage on Breakthrough: New Ovarian Cancer Drug Achieves Remarkable 55% Response Rate in Clinical Trial - Stock Titan

Breakthrough: New Ovarian Cancer Drug Achieves Remarkable 55% Response Rate in Clinical Trial  Stock Titan

Breakthrough: New Ovarian Cancer Drug Achieves Remarkable 55% Response Rate in Clinical Trial - Stock Titan

Click here to get full coverage on Transactions in connection with share buy-back program - GlobeNewswire

Transactions in connection with share buy-back program  GlobeNewswire

Transactions in connection with share buy-back program - GlobeNewswire

Click here to get full coverage on Genmab stock price target cut to $35 at H.C. Wainwright By Investing.com - Investing.com South Africa

Genmab stock price target cut to $35 at H.C. Wainwright By Investing.com  Investing.com South Africa

Genmab stock price target cut to $35 at H.C. Wainwright By Investing.com - Investing.com South Africa

Click here to get full coverage on Is Genmab (GMAB) One of the Best Growth Stocks to Invest In According to Analysts? - Insider Monkey

Is Genmab (GMAB) One of the Best Growth Stocks to Invest In According to Analysts?  Insider Monkey

Is Genmab (GMAB) One of the Best Growth Stocks to Invest In According to Analysts? - Insider Monkey

Click here to get full coverage on Genmab stock drops as Bernstein downgrades (GMAB:NASDAQ) - Seeking Alpha

Genmab stock drops as Bernstein downgrades (GMAB:NASDAQ)  Seeking Alpha

Genmab stock drops as Bernstein downgrades (GMAB:NASDAQ) - Seeking Alpha

Click here to get full coverage on . The company, listed on the NASDAQ under the ticker NASDAQ:GMAB, has seen its product become a significant contributor to its revenue stream since DARZALEX® received regulatory approval. - Investing.com

. The company, listed on the NASDAQ under the ticker NASDAQ:GMAB, has seen its product become a significant contributor to its revenue stream since DARZALEX® received regulatory approval.  Investing.com

. The company, listed on the NASDAQ under the ticker NASDAQ:GMAB, has seen its product become a significant contributor to its revenue stream since DARZALEX® received regulatory approval. - Investing.com

Click here to get full coverage on Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab - GlobeNewswire

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab  GlobeNewswire

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab - GlobeNewswire

Click here to get full coverage on Genmab A/S' (CPH:GMAB) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - simplywall.st

Genmab A/S' (CPH:GMAB) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?  simplywall.st

Genmab A/S' (CPH:GMAB) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - simplywall.st

Click here to get full coverage on Transactions With Shares and Linked Securities in Genmab - GlobeNewswire

Transactions With Shares and Linked Securities in Genmab  GlobeNewswire

Genmab AS (GMAB)

Price Chart

Key Statistics

Technicals

About GMAB

Latest News

Genmab AS (GMAB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Initiatives - Yahoo Finance

Genmab (GMAB) Receives Revised Price Target from H.C. Wainwright - GuruFocus

Where are the Opportunities in (GMAB) - news.stocktradersdaily.com

Advanced Charts

Top Gainers

Top Losers